Growth Factors, Curcumin and Colon Carcinogenesis
生长因子、姜黄素和结肠癌发生
基本信息
- 批准号:7022436
- 负责人:
- 金额:$ 21.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-02-06 至 2010-01-31
- 项目状态:已结题
- 来源:
- 关键词:angiospermsapoptosisautocrinebiological signal transductioncarcinogenesiscell growth regulationcell linecell proliferationcolon neoplasmscrosslinkenzyme induction /repressiongastrinsgenetically modified animalshormone regulation /control mechanisminsulinlike growth factorintestinal mucosalaboratory mousemedicinal plantsmitogen activated protein kinasemolecular oncologyneoplastic cellnutrition aspect of cancernutrition related tagphosphorylationplant extractssmall interfering RNA
项目摘要
DESCRIPTION (provided by applicant): We now know that progastrins (PG) and insulin-like growth factors (IGFs) exert potent proliferative and anti- apoptotic effects on colon cancer (CRC) cells and can potentially function as co-carcinogens during all phases of colorectal carcinogenesis. Dietary agents, such as curcumin, inhibit the growth of CRC cells and inhibit colon carcinogenesis at both the pre-malignant and post-malignant stages of the disease. It is, however, not known if curcumin can inhibit the growth factor effects of autocrine and/or endocrine PG and IGF-II during colon carcinogenesis. Our preliminary studies suggest that the inhibitory effects of curcumin are attenuated in the presence of growth factors, such as IGF-II and PG; surprisingly the degree of attenuation was significantly higher in the presence of IGF-II than in the presence of PG. Therefore, the major hypothesis of our grant proposal is that the inhibitory efficacy of curcumin will be dictated by either the circulating growth factor profile of animal models or by the autocrine growth factors in CRC cells. To address this hypothesis, in Aim 1, we will develop isogenic cell lines that either express PG or IGF-II, and examine the pro-apoptotic and anti-proliferative potency of curcumin on these cells. Inhibitory effects of curcumin on intact colonic crypt cells, prepared from either transgenic mice over-expressing PG or IGFs or prepared from wild type mice, will also be examined. In Aim 2, we will examine dose-dependent effects of dietary curcumin against all phases of colon carcinogenesis in transgenic mice over-expressing PG or IGF-II, either in the circulation or locally within the intestinal mucosa. The intracellular pathways that mediate anti-apoptotic vs proliferative effects of PG and IGFs, on CRC and intestinal epithelial (IEC) cells, are being currently examined in our laboratory. The mechanisms by which curcumin inhibits the growth factor effects of IGFs and PG are unknown at the present time. In Aim 3 we will examine the effect of curcumin on the phosphorylation/dephosphorylation of several kinases/phosphatases that are activated in response to PG or IGF-II in isogenic CRC and IEC cells. The above experiments will allow us to learn for the first time the relative effectiveness of curcumin on colon carcinogenesis in the presence of growth factors relevant to the etiology of the disease. The results of these studies are expected to help in developing mechanism-based strategies for preventative/treatment protocols for CRC using curcumin like agents.
描述(由申请人提供):我们现在知道,原胃泌素(PG)和胰岛素样生长因子(IGFs)对结肠癌(CRC)细胞具有强大的增殖和抗凋亡作用,并可能在结直肠癌发生的所有阶段作为共同致癌物起作用。膳食制剂,如姜黄素,抑制结直肠癌细胞的生长,并在疾病的恶性前期和恶性后阶段抑制结肠癌的发生。然而,目前尚不清楚姜黄素是否可以抑制结肠癌发生过程中自分泌和/或内分泌PG和IGF-II的生长因子作用。我们的初步研究表明,姜黄素的抑制作用在生长因子如IGF-II和PG的存在下减弱;令人惊讶的是,IGF-II存在时的抑制程度明显高于PG存在时的抑制程度。因此,我们的主要假设是,姜黄素的抑制功效将由动物模型的循环生长因子特征或CRC细胞中的自分泌生长因子决定。为了解决这一假设,在第1项研究中,我们将开发表达PG或IGF-II的等基因细胞系,并检测姜黄素对这些细胞的促凋亡和抗增殖能力。姜黄素对完整结肠隐窝细胞的抑制作用也将被检测,这些细胞是由过表达PG或IGFs的转基因小鼠或野生型小鼠制备的。在第2项研究中,我们将研究姜黄素在过表达PG或IGF-II的转基因小鼠中对结肠癌变所有阶段的剂量依赖性作用,无论是在循环中还是在肠粘膜内局部。我们的实验室目前正在研究介导PG和IGFs对结直肠癌和肠上皮(IEC)细胞的抗凋亡和增殖作用的细胞内通路。姜黄素抑制igf和PG的生长因子作用的机制目前尚不清楚。在Aim 3中,我们将研究姜黄素对等基因CRC和IEC细胞中响应PG或IGF-II而激活的几种激酶/磷酸酶的磷酸化/去磷酸化的影响。上述实验将使我们第一次了解姜黄素在与疾病病因相关的生长因子存在的情况下对结肠癌发生的相对有效性。这些研究的结果有望帮助开发基于机制的策略,用于使用姜黄素类药物预防/治疗结直肠癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pomila Singh其他文献
Pomila Singh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pomila Singh', 18)}}的其他基金
Growth Factors, Curcumin and Colon Carcinogenesis
生长因子、姜黄素和结肠癌发生
- 批准号:
7804539 - 财政年份:2006
- 资助金额:
$ 21.44万 - 项目类别:
Growth Factors, Curcumin and Colon Carcinogenesis
生长因子、姜黄素和结肠癌发生
- 批准号:
7800753 - 财政年份:2006
- 资助金额:
$ 21.44万 - 项目类别:
Growth Factors, Curcumin and Colon Carcinogenesis
生长因子、姜黄素和结肠癌发生
- 批准号:
7176219 - 财政年份:2006
- 资助金额:
$ 21.44万 - 项目类别:
Growth Factors, Curcumin and Colon Carcinogenesis
生长因子、姜黄素和结肠癌发生
- 批准号:
7547753 - 财政年份:2006
- 资助金额:
$ 21.44万 - 项目类别:
Growth Factors, Curcumin and Colon Carcinogenesis
生长因子、姜黄素和结肠癌发生
- 批准号:
7342501 - 财政年份:2006
- 资助金额:
$ 21.44万 - 项目类别:
AnnexinA2/progastrin and stem cells: dietary cancer prevention
膜联蛋白 A2/前胃泌素和干细胞:饮食癌症预防
- 批准号:
8715695 - 财政年份:2003
- 资助金额:
$ 21.44万 - 项目类别:
AnnexinA2/progastrin and stem cells: dietary cancer prevention
膜联蛋白 A2/前胃泌素和干细胞:饮食癌症预防
- 批准号:
8107838 - 财政年份:2003
- 资助金额:
$ 21.44万 - 项目类别:
AnnexinA2/progastrin and stem cells: dietary cancer prevention
膜联蛋白 A2/前胃泌素和干细胞:饮食癌症预防
- 批准号:
8527898 - 财政年份:2003
- 资助金额:
$ 21.44万 - 项目类别:
AnnexinA2/progastrin and stem cells: dietary cancer prevention
膜联蛋白 A2/前胃泌素和干细胞:饮食癌症预防
- 批准号:
8712822 - 财政年份:2003
- 资助金额:
$ 21.44万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
- 批准号:31970691
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
- 批准号:31900527
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
姜黄素与TRAIL的协同抗肿瘤机制研究
- 批准号:31101223
- 批准年份:2011
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
- 批准号:81100502
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Complement Protein C1q Regulation of Macrophage Metabolic Pathways
补体蛋白 C1q 对巨噬细胞代谢途径的调节
- 批准号:
10629550 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Ex vivo whole ovary culture system for screening gonadotoxicity during drug development
用于在药物开发过程中筛选性腺毒性的离体全卵巢培养系统
- 批准号:
10823136 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Mechanisms and therapeutic targeting of osteoimmune functions of RANKL in breast cancer
RANKL在乳腺癌中的骨免疫功能的机制和治疗靶点
- 批准号:
10586000 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
开发天然化合物大黄素治疗酒精性心肌病
- 批准号:
10597858 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Effectors of protein kinase C-mediated tumor progression
蛋白激酶 C 介导的肿瘤进展的效应器
- 批准号:
10543367 - 财政年份:2022
- 资助金额:
$ 21.44万 - 项目类别:
Project I: Systems analysis of tumor-stroma interactions in brain metastasis
项目一:脑转移中肿瘤-基质相互作用的系统分析
- 批准号:
10705775 - 财政年份:2022
- 资助金额:
$ 21.44万 - 项目类别:
Development of new therapeutic approaches for endometrial cancer
子宫内膜癌新治疗方法的开发
- 批准号:
10522572 - 财政年份:2022
- 资助金额:
$ 21.44万 - 项目类别:














{{item.name}}会员




